BioSante Pharmaceuticals to Present at Upcoming Conferences

  
    
  
  
    
      BioSante Pharmaceuticals (AMEX:BPA) today announced that Stephen M. 
      Simes, president and chief executive officer, will present a corporate 
      overview at two upcoming conferences. The conferences are:
    
    
      
        The Bio International Convention on May 8, 2007 at 3:45 p.m. EDT at 
        the Boston Convention and Exhibition Center.
      
      
        The Rodman & Renshaw Global Healthcare Conference on May 14, 2007 at 
        12:15 p.m. local time at the Le Meridien Hotel in Monte Carlo.
      
    
    
      A live audio webcast of BioSante’s 
      presentation at these conferences can be accessed on the internet by 
      visiting www.biosantepharma.com. 
      An archive of these presentations will be available at the same address.
    
    
      The Bio International Convention is expected to attract more than 20,000 
      biotech leaders, investors and analysts from around the world and 
      features over 1,000 speakers. The Rodman & Renshaw Global Healthcare 
      Conference has over 200 companies presenting to investors, stock 
      analysts and industry representatives from around the world.
    
    
      About BioSante Pharmaceuticals, Inc.
    
    
      BioSante is developing a pipeline of hormone therapy products to treat 
      both men and women. These hormone therapy products are gel formulations 
      for transdermal administration that deliver bio-identical estradiol and 
      testosterone. BioSante's lead products include Elestrin™ 
      (estradiol gel), developed through FDA approval by BioSante, indicated 
      for the treatment of moderate-to-severe vasomotor symptoms associated 
      with menopause, and LibiGel® 
      (transdermal testosterone gel) in Phase III clinical development for the 
      treatment of female sexual dysfunction (FSD). The current market in the 
      U.S. for estrogen and testosterone products is approximately $2.5 
      billion. The transdermal gel formulations used in the women's gel 
      products are licensed by BioSante from Antares Pharma. The company also 
      is developing its calcium phosphate nanotechnology (CaP) for novel 
      vaccines, including hepatitis B, avian flu and biodefense vaccines for 
      toxins such as anthrax, as well as a system for delivering drugs via 
      alternative routes of administration. Additional information is 
      available online at: www.biosantepharma.com.